Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
February 13, 2025
07:30 PM - 09:00 PM PT
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
February 14, 2025
06:00 PM - 08:00 PM PST
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
